CareDx, Inc. announced that Keith Kennedy will serve as the company’s Chief Operating Officer and Chief Financial Officer, effective February 26, 2026. Kennedy, who has been the company’s COO since September 2024, brings more than two decades of executive experience in global diagnostics, biopharma services, and contract development and manufacturing, having previously held CFO positions at PharmaLogic Holdings and Veracyte.
The appointment follows the resignation of former CFO Nathan Smith, who stepped down during the Q4 2025 earnings call and will transition out after the filing of the company’s Form 10‑K. Kennedy’s dual‑role appointment is intended to streamline operations and finance functions as CareDx continues to scale its integrated transplant diagnostics ecosystem.
CareDx reported Q4 2025 revenue of $108.4 million, a 25% year‑over‑year increase that beat the analyst estimate of $102.58 million by $5.81 million. Non‑GAAP earnings per share were $0.12, missing the consensus estimate of $0.24 by $0.12. The revenue beat was driven by strong demand for CareDx’s core transplant diagnostics products, while the EPS miss reflected higher operating expenses and a one‑time charge related to restructuring costs. Compared with Q4 2024, revenue grew from $86.6 million and EPS fell from $0.18 to $0.12, indicating a shift in cost structure as the company invests in new product lines.
For 2026, CareDx is guiding full‑year revenue between $420 million and $444 million, representing roughly 14% year‑over‑year growth at the midpoint, and adjusted EBITDA between $30 million and $45 million. The guidance includes an estimated $7.5 million revenue impact from the anticipated implementation of the local coverage determination policy, underscoring the company’s focus on navigating regulatory changes while maintaining growth momentum.
Kennedy’s appointment signals CareDx’s intent to consolidate leadership and reinforce financial stewardship amid a dynamic regulatory environment. By combining the COO and CFO functions, the company aims to accelerate decision‑making, improve margin discipline, and support strategic growth initiatives such as expanding its transplant diagnostics platform and pursuing new market opportunities. The move also provides continuity in financial oversight during a period of significant market developments, positioning CareDx to capitalize on demand for its diagnostics solutions while managing cost pressures and regulatory headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.